TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03007940

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Coach Site Visit
Description: The coach will conduct a one-day on site visit and will review the walk-through and DDCAT assessment results, and help the change team design an initial change project with Plan-Do-Study-Act (PDSA) cycles. The site visit will use a standardized agenda to ensure NIATx fidelity.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Walk-through
Description: Walk-Through: Provider change teams will participate in a coach-led webinar that introduces how to conduct a NIATx walk-through from the co-occurring patient perspective and how to write up results using a standard report format. The walk-through will be conducted within two months of the initial coach site visit.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Learning Sessions
Description: The study includes two one-day coach-led learning sessions. The learning sessions promote peer-to-peer sharing about specific goals and objectives. The agenda is tailored to specific treatment service integration issues. The first coach-led learning session teaches providers how to use NIATx process improvement strategies. Providers share walk-through results and initial change projects. Skill development activities include how to: identify change opportunities, use specific tools (e.g., flowcharting), develop PDSA cycles, effectively use data and learning successful change strategies. At the final session, providers present results, sustainment plans, and identify ways for the group to continue to interact.
Study: NCT00947167

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pertuzumab
Description: 840 mg, 420 mg, iv

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib
Description: 150 mg, PO
Study: NCT03007940

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Coaching
Description: A NIATx coach leads the active 12 month implementation phase. The coach works with executive directors, change leaders and teams. After the site visit, a coach will hold individual monthly coaching calls (10 hours in total), and participate in group coaching calls (2 hours in total). In the individual calls, the coach and change team review change projects; discuss successes; and identify ideas for future change projects. Group coaching calls involve change leaders from multiple providers. On these calls, change leaders will discuss common change-related issues, progress, and exchange innovative implementation strategies with their peers. These calls provide opportunities for the coach to share new strategies and discuss implementation issues such as the development of a sustain plan.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Business as Usual
Description: Programs in this intervention will continue with their own plans without coaching support to integrate services for individuals with co-occurring substance abuse and mental health disorders. Once the programs in the wait-list control group receive the NIATx Strategy, they will participate in all of the interventions listed above.
Study: NCT01171534

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DermaClose fasciotomy closure
Description: The DermaClose device provides continuous expanding of the skin around the wound until it has stretched enough to allow the skin edges to be sutured closed.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Vessel loop
Description: Vessel loops and staples for fasciotomy closure
Study: NCT03991975

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib
Description: a multi-target receptor tyrosine kinase inhibitor.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQB2450
Description: TQB2450 is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1), which prevents PD-L1 from binding to PD-1 and B7.1 receptors on T cell surface, restores T cell activity, thus enhancing immune response and has potential to treat various types of tumors.
Study: NCT02530840

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: medical team
Description: Lowering HbA1c by behavioral changes in meetings with the medical team.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: peers group
Description: Lowering HbA1c by behavioral changes in meetings with the peers group.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SMS notification
Description: Lowering HbA1c by behavioral changes in meetings with the SMS notification
Study: NCT01693978

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prolonged Exposure Therapy
Description: Prolonged Exposure Therapy is considered the gold standard treatment for PTSD in psychiatry. It uses a cognitive-behavioral approach that repeatedly and systematically exposes patients to memories of their traumatic events to reduce fear and arousal. The PE therapy offered in this study will be based on procedures used by Foa and colleagues, described in their book-length treatment manual (Foa, Hembree, \& Rothbaum, 2007).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Prolonged Exposure Therapy
Description: Prolonged Exposure Therapy is considered the gold standard treatment for PTSD in psychiatry. It uses a cognitive-behavioral approach that repeatedly and systematically exposes patients to memories of their traumatic events to reduce fear and arousal. The PE therapy offered in this study will be based on procedures used by Foa and colleagues, described in their book-length treatment manual (Foa, Hembree, \& Rothbaum, 2007).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Voucher-Based Reinforcement
Description: Those in the PE+CM condition will also be able to earn voucher-based incentives for each therapy session that they attend as scheduled, with a maximum of $480 for full adherence to all sessions. Specifically, participants will earn $30 for attending Session 1, $40 for attending Session 2, $50 for attending Session 3, and $60 for attending Sessions 4 through 9. There will be no payment for Sessions 10 through 12. Because it is very important that participants attend sessions on schedule, voucher values will be reset starting from $30 if participants miss a scheduled session. Vouchers can be exchanged for goods and services in the community (e.g., gift cards to local retailers).
Study: NCT03973060

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Concentric-eccentric muscular work
Description: For muscular contraction, the physiotherapist carried out 12 repetitions with one minute rest between series and series, total working time of 12 minutes.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Concentric-eccentric muscular work
Description: For muscular contraction, the physiotherapist carried out 12 repetitions with one minute rest between series and series, total working time of 12 minutes.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Concentric-eccentric muscular work
Description: For muscular contraction, the physiotherapist carried out 12 repetitions with one minute rest between series and series, total working time of 12 minutes.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Concentric-eccentric muscular work
Description: For muscular contraction, the physiotherapist carried out 12 repetitions with one minute rest between series and series, total working time of 12 minutes.

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Genetic polymorphism
Description: Genetic polymorphism study by Polymerase Chain Reaction (PCR) to determine whether the genetic makeup of individuals for the improvement of muscular work in the results of the study.

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Genetic polymorphism
Description: Genetic polymorphism study by Polymerase Chain Reaction (PCR) to determine whether the genetic makeup of individuals for the improvement of muscular work in the results of the study.

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Genetic polymorphism
Description: Genetic polymorphism study by Polymerase Chain Reaction (PCR) to determine whether the genetic makeup of individuals for the improvement of muscular work in the results of the study.
Study: NCT03583190

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Orthopedic manual therapy
Description: Orthopedic Manual Therapy (OMT) that includes either mobilization or manipulation to the cervical spine applied pragmatically to the most symptomatic level.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Thoracic Manipulation
Description: Thoracic Manipulation (applied pragmatically) to the levels determined to be provocative or hypomobile.
Study: NCT03973060

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Genetic polymorphism
Description: Genetic polymorphism study by Polymerase Chain Reaction (PCR) to determine whether the genetic makeup of individuals for the improvement of muscular work in the results of the study.
Study: NCT01009619

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin
Description: Azithromycin 250 mg daily during 5 days followed by 250 mg three times a week on Mon., Wed. and Fri. during study-period.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo once daily during 5 days, followed by one placebo three times a week on Mon., Wed. and Fri during rest of study-period.
Study: NCT00836121

Intervention type: PROCEDURE
Intervention: right thoracotomy
Description: complete surgical resection
Study: NCT01766505

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Candemore tablet
Description: Candemore tablet 8, 16, or 32mg/tab, per oral, a tablet once a day during 16 weeks.~dosage is depends on the sitting blood pressure.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cozzar tablet
Description: Cozzar tablet: 8mg, 16mg, 32mg/tablet, per oral, a tablet a day during 16 weeks dosage depends on sitting blood pressure
Study: NCT02050204

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention
Description: The intervention was a 3-month structural and social change process designed to increase employee control over work time and family supportive supervisory behaviors (Kossek et al., in press). The change process was an integration of two previously evaluated interventions (Hammer et al., 2011; Kelly et al., 2011). A facilitator led 8 hrs of participatory sessions to transition employees from a time-based to a results-based work culture. Supervisors participated in all change activities plus 4hrs of training in supportive supervision. Training in family supportive supervision was implemented with behavioral computer-based training (cTRAIN, NWeta, Lake Oswego, OR) followed by 2 rounds of goal-setting and behavioral self-monitoring using an iPod Touch (Habitrack, OHSU, Portland, OR).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention
Description: The intervention was a 3-month structural and social change process designed to increase employee control over work time and family supportive supervisory behaviors (Kossek et al., in press). The change process was an integration of two previously evaluated interventions (Hammer et al., 2011; Kelly et al., 2011). A facilitator led 8 hrs of participatory sessions to transition employees from a time-based to a results-based work culture. Supervisors participated in all change activities plus 4hrs of training in supportive supervision. Training in family supportive supervision was implemented with behavioral computer-based training (cTRAIN, NWeta, Lake Oswego, OR) followed by 2 rounds of goal-setting and behavioral self-monitoring using an iPod Touch (Habitrack, OHSU, Portland, OR).
Study: NCT03868644

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Voluntary Counseling and Testing for HIV (VCT)
Description: Youth are offered VCT conducted onsite via mobile clinics in accordance with Kenya National HIV Testing Guidelines by certified VCT counselors trained by the National AIDS and STI Control Program (NASCOP).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Voluntary Counseling and Testing for HIV (VCT)
Description: Youth are offered VCT conducted onsite via mobile clinics in accordance with Kenya National HIV Testing Guidelines by certified VCT counselors trained by the National AIDS and STI Control Program (NASCOP).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Condoms
Description: Youth are offered 50 packages containing 3 condoms each of Trust brand condoms free of charge.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Condoms
Description: Youth are offered 50 packages containing 3 condoms each of Trust brand condoms free of charge.
Study: NCT02909608

Intervention type: OTHER
Intervention: No interventions / observations only
Description: This is an observational study only

Intervention type: OTHER
Intervention: No interventions / observations only
Description: This is an observational study only
Study: NCT03084783

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Participants receive dexamethasone 10mg intravenously 6 hourly for 4 days.
Study: NCT01081418

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Assertive Community Treatment (ACT)
Description: ACT was structured and implemented according to guidelines of the Assertive Community Treatment Association (ACTA). Team members were highly educated psychosis experts consisting of a consultant psychiatrist, a psychiatrist, two psychologists, and a nurse, all of which received training in cognitive behavioral (CBT), dynamic, and/or family psychotherapy. Study participants could use all treatment options within the integrated care program such as psychoeducation groups, social skills training, family groups, motivational addiction therapy, meta-cognitive training etc.
Study: NCT02131688

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitoxantrone Hydrochloride Liposome
Study: NCT03284099

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ACEi, ARB
Description: To take the ACEis or ARBs before bedtime instead of in the morning

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACEi, ARB
Description: To take the ACEis or ARBs before bedtime instead of in the morning
Study: NCT04134390

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib
Description: Subjects will receive cabozantinib 40mg p.o. as long as they continue to experience clinical benefit or until unacceptable toxicity, the need for alternative anticancer treatment, or other reasons for treatment discontinuation
Study: NCT02807675

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CVT-301, LIP
Description: All subjects will receive 1 dose of CVT-301 and 1 dose of placebo inhalation powder, to be taken concomitantly with their standard oral medication in 2 dosing periods. The order of treatment will be randomized, with subjects assigned to 1 of 2 sequences CVT-301 (A) administered first, followed by placebo (B), or the reverse order (BA)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: All subjects will receive 1 dose of CVT-301 and 1 dose of placebo inhalation powder, to be taken concomitantly with their standard oral medication in 2 dosing periods. The order of treatment will be randomized, with subjects assigned to 1 of 2 sequences CVT-301 (A) administered first, followed by placebo (B), or the reverse order (BA)
Study: NCT04181814

Intervention type: DEVICE
Intervention: Ultrasound
Description: Use ultrasound to assess gastric contents in diabetic patients before anesthesia
Study: NCT03583190

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Thoracic Manipulation
Description: Thoracic Manipulation (applied pragmatically) to the levels determined to be provocative or hypomobile.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Clinicians select 1 active range of motion exercise for the cervical spine, deep cervical flexion endurance exercise, and 5 upper extremity exercises (from a set of 10). Additionally, patients will be assigned a headache management technique.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: Clinicians select 1 active range of motion exercise for the cervical spine, deep cervical flexion endurance exercise, and 5 upper extremity exercises (from a set of 10). Additionally, patients will be assigned a headache management technique.
Study: NCT01292902

Intervention type: OTHER
Group type: OTHER
Intervention: inspiratory muscle exercise
Description: To conduct the exercise to the inspiratory muscles was used for IMT Threshold ® device (Threshold Inspiratory Muscle Trainer, HealthScan Products Inc., Cedar Grove, New Jersey) is one of the most used for training of inspiratory muscles in patients with several pathologies such as ICC.Threshold ® has been engaged in the patient's mouth by a mouthpiece, with the nose occluded by a nose clip. The exercise time was 3 minutes. During this period, participants were encouraged to only breathe through the mouth and maintain a respiratory rate between 12 and 16ipm. The exercise would be stopped if HR increased more than 20% and / or SpO2 \< 88%.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: inspiratory muscle exercise
Description: Equal to the group with chronic heart failure.
Study: NCT01691651

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Subcutaneous injection of botulinum toxin type A
Description: Subcutaneous injection of botulinum toxin type A (2.5 units per application point) at two points in a nasal and temporal extent of the orbicularis muscle will be performed in the Botulinum toxin type A group.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botulinum Toxin Type A
Description: 2.5 units per point of application at two points in a nasal and temporal extent of the orbicularis muscle.
Study: NCT01626716

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: care management
Description: patients who assigned to the intervention group will take 7 times phone calls from case manager
Study: NCT02308878

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile health cognitive stimulation
Study: NCT04320667

Intervention type: DIAGNOSTIC_TEST
Intervention: Flow cytometry analysis of urine samples
Description: Urine samples will be conserved and frozen upon arrival. All samples will be stained according to T cell and TEC (tubular epithelial cells) panel with fluorochromes.~T cell panel: CD3, CD4, CD8, CCR7, CD45RO, CD28, CD279; TEC panel: vimentin, cytokeratine, CD10, CD13, CD227, CD326

Intervention type: DIAGNOSTIC_TEST
Intervention: Flow cytometry analysis of urine samples
Description: Urine samples will be conserved and frozen upon arrival. All samples will be stained according to T cell and TEC (tubular epithelial cells) panel with fluorochromes.~T cell panel: CD3, CD4, CD8, CCR7, CD45RO, CD28, CD279; TEC panel: vimentin, cytokeratine, CD10, CD13, CD227, CD326
Study: NCT03772873

Intervention type: PROCEDURE
Intervention: minimally invasive pilonidal excision
Description: MIPE procedure with trephine excision of pits and sinuses
Study: NCT00121875

Intervention type: DRUG
Intervention: somatropin (rDNA)
Description: Form/Strength: 10 mg aqueous suspension; 5 mg/ml~Dosage/Frequency: 0.35 mg/kg/week, daily divided doses~Duration: 6 months with 3-month washout period

Intervention type: DRUG
Intervention: somatropin (rDNA)
Description: Form/Strength: 10 mg aqueous suspension; 5 mg/ml~Dosage/Frequency: 0.35 mg/kg/week, daily divided doses~Duration: 6 months with 3-month washout period
Study: NCT03583190

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient Education
Description: Patients will receive education regarding their headache condition, proper performance of their symptom management technique, posture.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Patient Education
Description: Patients will receive education regarding their headache condition, proper performance of their symptom management technique, posture.
Study: NCT04053738

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Anti-snoring bed
Description: The mattress shape is adjusted using a custom made intelligent anti-snoring bed, which is able to detect snoring sound and change the position of the user whenever snoring occurs.
Study: NCT01568814

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Low volume PEG
Description: low volume polyethylene glycol 2 liter one time

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: high volume PEG
Description: high volume polyethylene glycol 4 lilter split-dosing 2L/2L two times
Study: NCT02280278

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radical surgery

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Radical surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adjuvant chemotherapy

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cytokine-induced killer cell immunotherapy
Study: NCT01332071

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosiglitazone Maleate + Metformin 2 miligrams (mg) + 500 mg
Description: Avandamet reference product

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosiglitazone Maleate + Metformin 4 miligrams (mg) + 1000 mg
Description: Avandamet test product
Study: NCT01445678

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CXA-201 and metronidazole
Description: CXA-201 IV infusion (1500mg q8h) and metronidazole IV infusion (500mg q 8h) for 4-14 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Meropenem
Description: Meropenem IV infusion (1000mg q8h) for 4-14 days
Study: NCT03644238

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Oral Glucose Tolerance Test
Description: 75g of glucose is consumed

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Oral Glucose Tolerance Test
Description: 75g of glucose is consumed

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Inactivity
Description: Lying or sitting down.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity
Description: 20 minutes of fixed intensity exercise on a bicycle ergometer.
Study: NCT04152096

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rheosorbilact®
Description: Administered intravenously (with speed 40-60 drip per minute) at a dose of 600 to 1,000 ml (10 to 15 ml/kg body weight per 24 hours) for 3 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ringer lactate
Description: Administered intravenously (with speed 40-60 drip per minute) at a dose of 1,000 to 2,500 ml (15 to 40 ml/kg body weight per 24 hours) for 3 days.
Study: NCT01393197

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Therapeutic Chemoembolization
Description: Transcatheter Arterial Chemoembolization

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Therapeutic Chemoembolization
Description: Transcatheter Arterial Chemoembolization

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Therapeutic Chemoembolization
Description: Transcatheter Arterial Chemoembolization
Study: NCT04509622

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Tablet; Oral
Study: NCT02233413

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active LLLT helmet application
Description: LED helmet applied with light activated